US20170304388A1 - New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition - Google Patents

New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition Download PDF

Info

Publication number
US20170304388A1
US20170304388A1 US15/521,536 US201515521536A US2017304388A1 US 20170304388 A1 US20170304388 A1 US 20170304388A1 US 201515521536 A US201515521536 A US 201515521536A US 2017304388 A1 US2017304388 A1 US 2017304388A1
Authority
US
United States
Prior art keywords
cancer
hcl
group
agent
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/521,536
Inventor
Chiu-Hung Chen
Show-Mei CHUANG
Nai-Wan HSIAO
Ruei-Yue Liang
Xiao-Tong Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Launx Biomedical Co Ltd
Original Assignee
Launx Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Launx Biomedical Co Ltd filed Critical Launx Biomedical Co Ltd
Priority to US15/521,536 priority Critical patent/US20170304388A1/en
Publication of US20170304388A1 publication Critical patent/US20170304388A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides new clinical indication of cardiovascular drugs, which were approved by FDA. Particularly, the present invention demonstrates that the cardiovascular drugs can effectively inhibit a variety of cancers.
  • Cancer is the most popular disease cause of death in the world.
  • the cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue.
  • the medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy.
  • the cancer drug is inhibit the cancer cells' duplication and split to prevent the tumor growth and metastasis.
  • the combination of chemotherapies and several targeted therapies were selected; try to eliminate cancer cells more effectively, by means of different mechanisms.
  • the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure.
  • cardiovascular disease aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases. For example, some cardiovascular drugs can treat high blood pressure, and other cardiovascular drugs can promote blood flow in patients with heart failure.
  • the human cancer cells and normal cells often have different characteristics, the differences in patterns or mechanism variation might be seen as a foreign invader.
  • the different cancel cells are located in different locations and the statuses of variations are related to the located environment.
  • the inventors are the first person to propose the use of antibiotic drugs to inhibit the cancer cell growth.
  • the manufacturing of the drug is also a big problem.
  • problems need to overcome, such as drug safety, patient selection, trial dose and other issues.
  • Even the drug has approved by the FDA and sales on the market, there still possibly face the situation of the poor drug response in patients.
  • the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
  • the present invention provides a usage of existing cardiovascular drugs, which have passed clinical trials.
  • the cardiovascular drugs can be classified to ten categories based on the features, includes: peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant and thrombolytic agent, cardiac tonic, intravenous (hemorrhoids) therapeutic agent.
  • Peripheral vasodilator reaming enhancer which can directly or indirectly effect on peripheral blood vessels to increase blood flow, includes: Cilnidipine, Minoxidil, Prazosin HCl, Sildenafil citrate, Tadalafil (Cialis), Nicorandil (Ikorel), Lacidipine (Lacipil, Motens), Benidipine hydrochloride, Cilazapril monohydrate (Inhibace), Fosinopril sodium (Monopril), Almotriptan malate (Axert), Milrinone (Primacor), Avanafil, Lomerizine HCl, Histamine Phosphate, Chromocarb and Pinacidil.
  • Angiotensin converting agent inhibitor which is used to inhibit ACE activity and reduce the production of vasopressin II, so as to reduce the bradykinin hydrolysis, lead to vasodilatation, blood volume, and decrease blood pressure, includes: Benazepril hydrochloride, Losartan potassium, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Candesartan (Atacand), Olmesartan medoxomil (Benicar), Enalaprilat dehydrate, Telmisartan (Micardis), Ramipril (Altace), Valsartan (Diovan), Enalapril maleate (Vasotec), Candesartan cilexetil (Atacand), Conivaptan HCl (Vaprisol), Azilsartan Medoxomil (TAK-491) and Eprosartan Mesylate.
  • Hypotension and shock therapeutic agent which includes: L-Adrenaline (Epinephrine), DL-Adrenaline and Methoxamine HCl.
  • Diuretic which is used to increase the generation of urine and increase the excretion of human body water, includes: Bumetanide, Furosemide (Lasix), Metolazone(Zaroxolyn), Silodosin (Rapaflo), Chlorothiazide, Trichlormethiazide (Achletin), Torsemide (Demadex), Hydrochlorothiazide, Indapamide (Lozol), Dichlorphenamide (Diclofenamide), Amiloride hydrochloride dehydrate, Solifenacin succinate, Methyclothiazide, Benzthiazide, Meticrane, Bendroflumethiazide and Potassium Canrenoate.
  • Antiarrhythmic agent which is used to inhibit abnormal heartbeat rhythm (arrhythmia), such as atrial fibrillation, atrial flutter, and ventricular tachycardia (ventricular tachycardia) and ventricular fibrillation, includes: Adenosine (Adenocard), Dofetilide (Tikosyn), Amiodarone HCl, Ibutilide fumarate, Propafenone (Rytmonorm) and Disopyramide Phosphate.
  • Antiarralciton drug which is used to treat ischemic heart disease symptoms, includes Dexrazoxane Hydrochloride, Ranolazine dihydrochloride, Nisoldipine (Sular), Ranolazine (Ranexa), Acadesine, Nifedipine (Adalat), Amlodipine besylate (Norvasc), Diltiazem HCl (Tiazac), Ticagrelor and Oxprenolol HCl
  • Antihypertensive agent is a medicament for hypertension treatment, which is used to prevent high blood pressure complications, such as stroke and myocardial infarction, includes: Bisoprolol, Doxazosin mesylate, Alfuzosin hydrochloride (Uroxatral), Nebivolol (Bystolic), Reserpine, Methyldopa (Aldomet), Eplerenon, Nimodipine (Nimotop), Betaxolol hydrochloride (Betoptic), Carvedilol, Metoprolol tartrate, Felodipine (Plendil), Amlodipine (Norvasc), Phentolamine mesilate, Imidapril (Tanatril) HCl, Aliskiren hemifumarate, Sodium Nitroprusside, Propranolol HCl, Levobetaxolol HCl, Esmolol HCl, (R)-(+)
  • Anticoagulant is the flag used to prevent blood coagulation (coagulation). Those substances exist in leeches and blood-sucking insects. Anticoagulants can treat thrombotic diseases, include: Prasugrel (Effient), Cilostazol, Nafamostat mesylate, Clopidogrel (Plavix), Apixaban, Aminocaproic acid (Amicar), Dipyridamole (Persantine), Phenindione (Rectadione), Ticlopidine HCl, Ozagrel HCl, Argatroban, Bexarotene, Gabexate mesylate and Ozagrel and Anisindione.
  • Cardiac tonic includes: Pimobendan (Vetmedin), Ampiroxicam, Digoxigenin and Pindolol.
  • Intravenous (hemorrhoids) therapeutic agent includes: Edaravone (MCI-186), Daidzein, Ginkgolide A and Bisacodyl.
  • the cancer is selected from lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer and blood cancer.
  • the effect concentration of the drug in the present invention is 20 mg/kg/day ⁇ 500 mg/kg/day.
  • FIG. 1 illustrates the analysis of cardiovascular drugs for cancer cells inhibition.
  • the present invention provides a usage of cardiovascular drugs for cancer inhibition pharmaceutical composition preparation, which feature is the pharmaceutical composition composed by an effective dosage of cardiovascular drug and a pharmaceutical acceptable salt.
  • the cardiovascular drug of the present invention includes: Lenalidomide Valproic acid sodium salt (Sodium valproate), Decitabine, Bisoprolol, Dexrazoxane Hydrochloride, Prasugrel (Effient), Benazepril hydrochloride, Bumetanide, Cilnidipine, Cilostazol, Doxazosin mesylate, Edaravone (MCI-186), Losartan potassium, Minoxidil, Nafamostat mesylate, Bimatoprost, Alfuzosin hydrochloride (Uroxatral), Clopidogrel (Plavix), Prazosin HCl, Ranolazine dihydrochloride, Sildenafil citrate, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Tadalafil (Cialis), Nebivolol (Bystolic), Pimobendan (Vetmedin), Candesartan (Ata
  • the cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer.
  • Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2 ⁇ 10 6 in cell culture plate/flask. Then, the culture medium for culturing the cell lines was added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The cell number was 3000 cells and the volume of the culture medium was 100 ul each well.
  • the cardiovascular drugs include peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, intravenous (hemorrhoids) therapeutic agent, are used to test the inhibition effect of cancer cell.
  • FIG. 1 the inhibition effects of different cardiovascular drugs on different cancer cells were different (shown as FIG. 1 ).
  • Adiphenine HCl Rivastigmine tartrate (Exelon), Detomidine HCl, Fosinopril sodium (Monopril), Almotriptan malate (Axert), Bexarotene, Gabexate mesylate, Rasagiline mesylate, Imidapril (Tanatril) HCl, Conivaptan HCl (Vaprisol), Ibutilide fumarate, Probucol, Arbidol HCl, S-(+)-Rolipram, Tebipenem pivoxil (L-084), Dichlorphenamide (Diclofenamide), Aliskiren hemifumarate, DL-Carnitine hydrochloride, D-Mannitol (Osmitrol), L-carnitine (Levocarnitine), Amantadine hydrochloride (Symmetrel), Clozapine (Clozaril), Milrinone (Primacor), Mitoxantrone Hydrochlor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of a cardiovascular drug or a pharmaceutical acceptable salt thereof. The cardiovascular drug is selected from the group consisting of peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, and intravenous (hemorrhoids) therapeutic agent. The cancer is selected from the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092768 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention provides new clinical indication of cardiovascular drugs, which were approved by FDA. Particularly, the present invention demonstrates that the cardiovascular drugs can effectively inhibit a variety of cancers.
    • BACKGROUND OF THE INVENTION
  • Cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy.
  • Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is inhibit the cancer cells' duplication and split to prevent the tumor growth and metastasis. In clinical treatment options, the combination of chemotherapies and several targeted therapies were selected; try to eliminate cancer cells more effectively, by means of different mechanisms. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure.
  • On the other side, treatment of cardiovascular disease aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases. For example, some cardiovascular drugs can treat high blood pressure, and other cardiovascular drugs can promote blood flow in patients with heart failure.
  • Based on the many years' experience of inventors, the human cancer cells and normal cells often have different characteristics, the differences in patterns or mechanism variation might be seen as a foreign invader. The different cancel cells are located in different locations and the statuses of variations are related to the located environment. Thus, the inventors are the first person to propose the use of antibiotic drugs to inhibit the cancer cell growth.
  • In contrast, these cardiovascular drugs have been used for decades and are recognized by FDA long time ago. These cardiovascular drugs already have been researched and analyzed to know the mechanism on human body. Therefore, the groundbreaking new application would be time-saving and cost effective if these drugs applied in treating cancer. Besides, the treatment effect would be improved if these drugs are used to combine with other treating method.
  • Otherwise, the manufacturing of the drug is also a big problem. When the drug starting the clinical trials, there are lots of problems need to overcome, such as drug safety, patient selection, trial dose and other issues. Even the drug has approved by the FDA and sales on the market, there still possibly face the situation of the poor drug response in patients. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
    • SUMMARY OF THE INVENTION
  • To solve the above problems, the present invention provides a usage of existing cardiovascular drugs, which have passed clinical trials.
  • The experiment results showed that the cardiovascular drugs had no toxicity or only little toxicity to normal cells. However, there are more studies need to be test to know that whether the cardiovascular drugs have selection between normal cells and cancer cells. Besides, not all the cardiovascular drugs could inhibit the growth of cancer cells under same condition, there are still lots of problems need to be overcame.
  • Term Definition
  • The cardiovascular drugs can be classified to ten categories based on the features, includes: peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant and thrombolytic agent, cardiac tonic, intravenous (hemorrhoids) therapeutic agent.
  • (1) Peripheral vasodilator reaming enhancer, which can directly or indirectly effect on peripheral blood vessels to increase blood flow, includes: Cilnidipine, Minoxidil, Prazosin HCl, Sildenafil citrate, Tadalafil (Cialis), Nicorandil (Ikorel), Lacidipine (Lacipil, Motens), Benidipine hydrochloride, Cilazapril monohydrate (Inhibace), Fosinopril sodium (Monopril), Almotriptan malate (Axert), Milrinone (Primacor), Avanafil, Lomerizine HCl, Histamine Phosphate, Chromocarb and Pinacidil.
  • (2) Angiotensin converting agent inhibitor, which is used to inhibit ACE activity and reduce the production of vasopressin II, so as to reduce the bradykinin hydrolysis, lead to vasodilatation, blood volume, and decrease blood pressure, includes: Benazepril hydrochloride, Losartan potassium, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Candesartan (Atacand), Olmesartan medoxomil (Benicar), Enalaprilat dehydrate, Telmisartan (Micardis), Ramipril (Altace), Valsartan (Diovan), Enalapril maleate (Vasotec), Candesartan cilexetil (Atacand), Conivaptan HCl (Vaprisol), Azilsartan Medoxomil (TAK-491) and Eprosartan Mesylate.
  • (3) Hypotension and shock therapeutic agent, which includes: L-Adrenaline (Epinephrine), DL-Adrenaline and Methoxamine HCl.
  • (4) Diuretic, which is used to increase the generation of urine and increase the excretion of human body water, includes: Bumetanide, Furosemide (Lasix), Metolazone(Zaroxolyn), Silodosin (Rapaflo), Chlorothiazide, Trichlormethiazide (Achletin), Torsemide (Demadex), Hydrochlorothiazide, Indapamide (Lozol), Dichlorphenamide (Diclofenamide), Amiloride hydrochloride dehydrate, Solifenacin succinate, Methyclothiazide, Benzthiazide, Meticrane, Bendroflumethiazide and Potassium Canrenoate.
  • (5) Antiarrhythmic agent, which is used to inhibit abnormal heartbeat rhythm (arrhythmia), such as atrial fibrillation, atrial flutter, and ventricular tachycardia (ventricular tachycardia) and ventricular fibrillation, includes: Adenosine (Adenocard), Dofetilide (Tikosyn), Amiodarone HCl, Ibutilide fumarate, Propafenone (Rytmonorm) and Disopyramide Phosphate.
  • (6) Antiarralciton drug, which is used to treat ischemic heart disease symptoms, includes Dexrazoxane Hydrochloride, Ranolazine dihydrochloride, Nisoldipine (Sular), Ranolazine (Ranexa), Acadesine, Nifedipine (Adalat), Amlodipine besylate (Norvasc), Diltiazem HCl (Tiazac), Ticagrelor and Oxprenolol HCl
  • (7) Antihypertensive agent is a medicament for hypertension treatment, which is used to prevent high blood pressure complications, such as stroke and myocardial infarction, includes: Bisoprolol, Doxazosin mesylate, Alfuzosin hydrochloride (Uroxatral), Nebivolol (Bystolic), Reserpine, Methyldopa (Aldomet), Eplerenon, Nimodipine (Nimotop), Betaxolol hydrochloride (Betoptic), Carvedilol, Metoprolol tartrate, Felodipine (Plendil), Amlodipine (Norvasc), Phentolamine mesilate, Imidapril (Tanatril) HCl, Aliskiren hemifumarate, Sodium Nitroprusside, Propranolol HCl, Levobetaxolol HCl, Esmolol HCl, (R)-(+)-Atenolol, Guanethidine Sulfate and Lofexidine HCl.
  • (8) Anticoagulant, thrombolytic agent is the flag used to prevent blood coagulation (coagulation). Those substances exist in leeches and blood-sucking insects. Anticoagulants can treat thrombotic diseases, include: Prasugrel (Effient), Cilostazol, Nafamostat mesylate, Clopidogrel (Plavix), Apixaban, Aminocaproic acid (Amicar), Dipyridamole (Persantine), Phenindione (Rectadione), Ticlopidine HCl, Ozagrel HCl, Argatroban, Bexarotene, Gabexate mesylate and Ozagrel and Anisindione.
  • (9) Cardiac tonic includes: Pimobendan (Vetmedin), Ampiroxicam, Digoxigenin and Pindolol.
  • (10) Intravenous (hemorrhoids) therapeutic agent includes: Edaravone (MCI-186), Daidzein, Ginkgolide A and Bisacodyl.
  • In one of the embodiments, the cancer is selected from lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer and blood cancer.
  • In one of the embodiment of the present invention, wherein the effect concentration of the drug in the present invention is 20 mg/kg/day˜500 mg/kg/day.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates the analysis of cardiovascular drugs for cancer cells inhibition.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a usage of cardiovascular drugs for cancer inhibition pharmaceutical composition preparation, which feature is the pharmaceutical composition composed by an effective dosage of cardiovascular drug and a pharmaceutical acceptable salt.
  • The cardiovascular drug of the present invention includes: Lenalidomide Valproic acid sodium salt (Sodium valproate), Decitabine, Bisoprolol, Dexrazoxane Hydrochloride, Prasugrel (Effient), Benazepril hydrochloride, Bumetanide, Cilnidipine, Cilostazol, Doxazosin mesylate, Edaravone (MCI-186), Losartan potassium, Minoxidil, Nafamostat mesylate, Bimatoprost, Alfuzosin hydrochloride (Uroxatral), Clopidogrel (Plavix), Prazosin HCl, Ranolazine dihydrochloride, Sildenafil citrate, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Tadalafil (Cialis), Nebivolol (Bystolic), Pimobendan (Vetmedin), Candesartan (Atacand), Apixaban, Reserpine, Furosemide (Lasix), Olmesartan medoxomil (Benicar), Pyridostigmine Bromide (Mestinon), Metolazone (Zaroxolyn), Silodosin (Rapaflo), Chlorothiazide, Methyldopa (Aldomet), Adenosine (Adenocard), Ezetimibe (Zetia), Enalaprilat dehydrate, Dofetilide (Tikosyn), Trichlormethiazide (Achletin), Aminocaproic acid (Amicar), Busulfan (Myleran, Busulfex), Torsemide (Demadex), Eplerenone, Hydrochlorothiazide, Gemfibrozil (Lopid), Indapamide (Lozol), Telmisartan (Micardis), Nimodipine (Nimotop), Nisoldipine (Sular), Pitavastatin calcium (Livalo), Simvastatin (Zocor), Ramipril (Altace), Fenofibrate (Tricor, Trilipix), Ranolazine (Ranexa), Acadesine, Acipimox, Nifedipine (Adalat), Amlodipine besylate (Norvasc), Clofibrate (Atromid-S), Betaxolol hydrochloride (Betoptic), Carvedilol, Daidzein, toprolol tartrate, Diltiazem HCl (Tiazac), Tranexamic acid (Transamin), Felodipine (Plendil), Valsartan (Diovan), Dipyridamole (Persantine), Amlodipine (Norvasc), Fluvastatin sodium (Lescol), Phenindione (Rectadione), Enalapril maleate (Vasotec), Nicorandil (Ikorel), Amiodarone HCl, Ticlopidine HCl, Lacidipine (Lacipil, Motens), Suplatast tosylate, Benidipine hydrochloride, Ginkgolide A, Candesartan cilexetil (Atacand), Phentolamine mesilate, Nimesulide, Cytidine, Bromhexine HCl, Tiopronin (Thiola), Ozagrel HCl, Argatroban, Mitiglinide calcium, Rosiglitazone HCl, Atorvastatin calcium (Lipitor), Famotidine (Pepcid), Cleviprex (Clevidipine), Cilazapril monohydrate (Inhibace), Adiphenine HCl, Rivastigmine tartrate (Exelon), Detomidine HCl, Fosinopril sodium (Monopril), Almotriptan malate (Axert), Bexarotene, Gabexate mesylate, Rasagiline mesylate, Imidapril (Tanatril) HCl, Conivaptan HCl (Vaprisol), Ibutilide fumarate, Probucol, Arbidol HCl, S-(+)-Rolipram, Tebipenem pivoxil (L-084), Dichlorphenamide (Diclofenamide), Aliskiren hemifumarate, DL-Carnitine hydrochloride, D-Mannitol (Osmitrol), L-carnitine (Levocarnitine), Amantadine hydrochloride (Symmetrel), Clozapine (Clozaril), Milrinone (Primacor), Mitoxantrone Hydrochloride, Novobiocin sodium (Albamycin), Ozagrel, Pancuronium (Pavulon), Propafenone (Rytmonorm), Quinine hydrochloride dehydrate, Spectinomycin hydrochloride, Xylazine HCl, L-Adrenaline (Epinephrine), DL-Adrenaline, Trospium chloride (Sanctura), Amiloride hydrochloride dehydrate, Cloxacillin sodium (Cloxacap), Zidovudine (Retrovir), Thiamphenicol (Thiophenicol), Oseltamivir phosphate (Tamiflu), Lonidamine, Peramivir Trihydrate, Carfilzomib (PR-171), Pazopanib, Fosaprepitant dimeglumine, Otilonium Bromide, Solifenacin succinate, Besifloxacin HCl (Besivance), Azilsartan Medoxomil (TAK-491), Creatinine, Adrenalone HCl, Ampiroxicam, Desloratadine, Avanafil, Bisacodyl, Methyclothiazide, Sodium Nitroprusside, Vitamin D3 (Cholecalciferol), Deferiprone, Propranolol HCl, Mefenamic acid, Ticagrelor, sulfacetamide sodium, Lomerizine HCl, Levobetaxolol HCl, Dexlansoprazole, Esmolol HCl, Eprosartan Mesylate, Histamine Phosphate, Sevelamer HCl, Deoxyarbutin, Clorprenaline HCL, Ethamsylate, Chromocarb, Mevastatin, Mexiletine HCl, Phenazopyridine HCl, (R)-(+)-Atenolol, Anisindione, Benzthiazide, Disopyramide Phosphate, Guanethidine Sulfate, Isoetharine Mesylate, Methoxamine HCl, Meticrane, Oxprenolol HCl, Pinacidil, Bendroflumethiazide, Potassium Canrenoate, Digoxigenin, Lofexidine HCl and Pindolol.
  • Cell Culture
  • Subculture the different types of cancer cells. The cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in cell culture plate/flask. Then, the culture medium for culturing the cell lines was added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The cell number was 3000 cells and the volume of the culture medium was 100 ul each well.
  • TABLE 1
    Cancer cell lines and the culture medium
    tumor Cell line Culture medium
    Lung cancer H1650 (Lung Adenocarcinoma) RPMI
    A549 (Lung Adenocarcinoma) DMEM
    Stomach cancer AGS (Gastric Adenocarcinoma) RPMI
    MKN-45 (Gastric Adenocarcinoma) RPMI
    Liver cancer HepG2 (Hepatocellular Carcinoma) DMEM
    Intestinal HCT116 (Colorectal Carcinoma) DMEM
    cancer LoVo (Colorectal Adenocarcinoma) DMEM
    Skin cancer A375 (Amelanotic Melanoma) DMEM
    Cervical cancer HeLa (Cervix Adenocarcinoma) DMEM
    Prostate cancer PC3 (Prostate Adenocarcinoma) DMEM
    Bladder cancer TSGH-8301 (Urinary Bladder Carcinoma) RPMI
    Breast cancer MCF7 (Mammary Gland, Adenocarcinoma) DMEM
    Leukemia HL-60 (Acute Promyelocytic Leukemia) RPMI
  • Cell Viability Analysis
  • Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well are 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculating the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the drugs. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the drugs.
  • Growth Inhibitory Effects on Cancer Cell Lines by Various Cardiovascular Drugs in the Present Invention
  • For cell viability analysis, the cardiovascular drugs include peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, intravenous (hemorrhoids) therapeutic agent, are used to test the inhibition effect of cancer cell.
  • The test result showed that lots of cardiovascular drugs had no effect on cancer cell lines growth inhibition (Table 2).
  • TABLE 2
    The cardiovascular drugs which do not have
    significant inhibitory effect to cancer cells
    Numbers of inhibitory
    cardiovascular drugs effect on cancer cell line
    Bisoprolol 0
    Benazepril hydrochloride 0
    Bumetanide 0
    Furosemide (Lasix) 0
    Trichlormethiazide (Achletin) 0
    Aminocaproic acid (Amicar) 0
    Indapamide (Lozol) 0
    Simvastatin (Zocor) 0
    Ramipril (Altace) 0
    Fenofibrate (Tricor, Trilipix) 0
    Acadesine 0
    Acipimox 0
    Ticlopidine HCl 0
    Adiphenine HCl 0
    Rivastigmine tartrate (Exelon) 0
    Detomidine HCl 0
    Gabexate mesylate 0
    Rasagiline mesylate 0
    S-(+)-Rolipram 0
    Tebipenem pivoxil (L-084) 0
    Aliskiren hemifumarate 0
    Milrinone (Primacor) 0
    Novobiocin sodium 0
    Ozagrel 0
    Pancuronium (Pavulon) 0
    Propafenone (Rytmonorm) 0
    Xylazine HCl 0
    L-Adrenaline (Epinephrine) 0
    Lonidamine 0
    Bisacodyl 0
    Sodium Nitroprusside 0
    Mefenamic acid 0
    Ticagrelor 0
    sulfacetamide sodium 0
    Levobetaxolol HCl 0
    Dexlansoprazole 0
    Chromocarb 0
    Guanethidine Sulfate 0
    Isoetharine Mesylate 0
  • Besides, the inhibition effects of different cardiovascular drugs on different cancer cells were different (shown as FIG. 1). According to the experiment, the Lenalidomide, Valproic acid sodium salt (Sodium valproate), Decitabine, Bisoprolol, Dexrazoxane Hydrochloride, Prasugrel (Effient), Benazepril hydrochloride, Bumetanide, Cilnidipine, Cilostazol, Doxazosin mesylate, Edaravone (MCI-186), Losartan potassium, Minoxidil, Nafamostat mesylate, Bimatoprost, Alfuzosin hydrochloride (Uroxatral), Clopidogrel (Plavix), Prazosin HCl, Ranolazine dihydrochloride, Sildenafil citrate, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Tadalafil (Cialis), Nebivolol (Bystolic), Pimobendan (Vetmedin), Candesartan (Atacand), Apixaban, Reserpine, Furosemide (Lasix), Olmesartan medoxomil (Benicar), Pyridostigmine Bromide (Mestinon), Metolazone (Zaroxolyn), Silodosin (Rapaflo), Chlorothiazide, Methyldopa (Aldomet), Adenosine (Adenocard), Ezetimibe (Zetia), Enalaprilat dehydrate, Dofetilide (Tikosyn), Trichlormethiazide (Achletin), Aminocaproic acid (Amicar), Busulfan (Myleran, Busulfex), Torsemide (Demadex), Eplerenone, Hydrochlorothiazide, Gemfibrozil (Lopid), Indapamide (Lozol), Telmisartan (Micardis), Nimodipine (Nimotop), Nisoldipine (Sular), Pitavastatin calcium (Livalo), Simvastatin (Zocor), Ramipril (Altace), Fenofibrate (Tricor, Trilipix), Ranolazine (Ranexa), Acadesine, Acipimox, Nifedipine (Adalat), Amlodipine besylate (Norvasc), Clofibrate (Atromid-S), Betaxolol hydrochloride (Betoptic), Carvedilol, Daidzein, toprolol tartrate, Diltiazem HCl (Tiazac), Tranexamic acid (Transamin), Felodipine (Plendil), Valsartan (Diovan), Dipyridamole (Persantine), Amlodipine (Norvasc), Fluvastatin sodium (Lescol), Phenindione (Rectadione), Enalapril maleate (Vasotec), Nicorandil (Ikorel), Amiodarone HCl, Ticlopidine HCl, Lacidipine (Lacipil, Motens), Suplatast tosylate, Benidipine hydrochloride, Ginkgolide A, Candesartan cilexetil (Atacand), Phentolamine mesilate, Nimesulide, Cytidine, Bromhexine HCl, Tiopronin (Thiola), Ozagrel HCl, Argatroban, Mitiglinide calcium, Rosiglitazone HCl, Atorvastatin calcium (Lipitor), Famotidine (Pepcid), Cleviprex (Clevidipine), Cilazapril monohydrate (Inhibace). Adiphenine HCl, Rivastigmine tartrate (Exelon), Detomidine HCl, Fosinopril sodium (Monopril), Almotriptan malate (Axert), Bexarotene, Gabexate mesylate, Rasagiline mesylate, Imidapril (Tanatril) HCl, Conivaptan HCl (Vaprisol), Ibutilide fumarate, Probucol, Arbidol HCl, S-(+)-Rolipram, Tebipenem pivoxil (L-084), Dichlorphenamide (Diclofenamide), Aliskiren hemifumarate, DL-Carnitine hydrochloride, D-Mannitol (Osmitrol), L-carnitine (Levocarnitine), Amantadine hydrochloride (Symmetrel), Clozapine (Clozaril), Milrinone (Primacor), Mitoxantrone Hydrochloride, Novobiocin sodium (Albamycin), Ozagrel, Pancuronium (Pavulon), Propafenone (Rytmonorm), Quinine hydrochloride dihydrate, Spectinomycin hydrochloride, Xylazine HCl, L-Adrenaline (Epinephrine), DL-Adrenaline, Trospium chloride (Sanctura), Amiloride hydrochloride dihydrate, Cloxacillin sodium (Cloxacap), Zidovudine (Retrovir), Thiamphenicol (Thiophenicol), Oseltamivir phosphate (Tamiflu), Lonidamine, Peramivir Trihydrate, Carfilzomib (PR-171), Pazopanib, Fosaprepitant dimeglumine, Otilonium Bromide, Solifenacin succinate, Besifloxacin HCl (Besivance), Azilsartan Medoxomil (TAK-491), Creatinine, Adrenalone HCl, Ampiroxicam, Desloratadine, Avanafil, Bisacodyl, Methyclothiazide, Sodium Nitroprusside, Vitamin D3 (Cholecalciferol), Deferiprone, Propranolol HCl, Mefenamic acid, Ticagrelor, sulfacetamide sodium, Lomerizine HCl, Levobetaxolol HCl, Dexlansoprazole, Esmolol HCl, Eprosartan Mesylate, Histamine Phosphate, Sevelamer HCl, Deoxyarbutin, Clorprenaline HCL, Ethamsylate, Chromocarb, Mevastatin, Mexiletine HCl, Phenazopyridine HCl, (R)-(+)-Atenolol, Anisindione, Benzthiazide, Disopyramide Phosphate, Guanethidine Sulfate, Isoetharine Mesylate, Methoxamine HCl, Meticrane, Oxprenolol HCl, Pinacidil, Bendroflumethiazide, Potassium Canrenoate, Digoxigenin, Lofexidine HCl and Pindolol showed significant inhibition effect on different cancer cell lines (shown as Table 3).
  • Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only, and various modifications might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.
  • TABLE 3
    The inhibitory effect of cardiovascular drugs on various cancer cell lines
    Item Name A375 HCT116 (WT) HepG2 HeLa AGS H1650 MKN-45 TSGH A549 MCF7 PC3 LoVo HL-60
    Bisoprolol 117.4 118.0 107.5 110.8 80.3 80.7 79.7 87.5 123.9 111.9 95.2 118.8 85.7
    Benazepril 104.0 60.0 93.0 75.9 76.7 61.6 103.3 77.5 81.8 126.1 80.7 96.0 93.6
    hydrochloride
    Bumetanide 67.6 66.8 86.0 79.5 69.9 105.2 98.8 92.6 88.2 116.3 72.7 98.6 98.3
    Furosemide (Lasix) 87.6 92.6 103.5 98.2 97.4 80.6 64.2 76.5 142.0 104.8 191.9 112.2 100.3
    Trichlormethiazide 128.4 111.5 95.1 85.7 79.3 76.7 71.0 95.6 106.3 64.2 122.3 107.3 102.2
    (Achletin)
    Aminocaproic acid 122.7 114.2 101.2 90.4 64.8 65.4 80.2 71.4 70.3 69.2 79.6 91.2 93.0
    (Amicar)
    Indapamide (Lozol) 64.8 80.0 84.0 67.9 109.2 86.7 104.9 85.0 105.8 65.5 76.8 92.7 101.2
    Simvastatin (Zocor) 114.5 124.2 113.3 103.6 85.6 114.7 79.4 101.0 126.3 81.5 91.8 99.9 69.0
    Ramipril (Altace) 120.3 108.3 105.6 84.3 99.8 135.0 84.0 114.2 99.6 82.4 103.5 81.9 107.3
    Fenofibrate (Tricor, 158.8 98.9 103.7 98.3 84.1 122.0 83.1 103.2 101.1 78.1 105.2 74.6 77.6
    Trilipix)
    Acadasine 99.1 88.7 103.1 88.4 75.4 100.9 81.5 99.7 117.1 84.7 94.8 80.9 110.1
    Acipimox 123.9 79.4 99.8 87.6 87.5 89.6 80.2 99.8 107.8 75.8 94.5 77.4 102.2
    Ticlopidine HCl 86.5 71.9 97.4 81.9 77.2 61.6 72.7 111.5 84.9 96.8 69.9 90.5 101.8
    Adiphenine HCl 87.6 133.9 95.5 96.4 109.0 118.7 95.7 82.0 86.8 102.9 102.2 95.7 105.0
    Rivastigmine tartrate 76.1 117.6 93.7 90.1 63.6 83.6 93.8 83.9 65.9 67.5 85.4 85.4 103.2
    (Exelon)
    Detomidine HCl 84.8 133.0 102.3 88.8 68.5 90.6 91.0 74.2 81.1 106.5 89.2 91.0 104.8
    Gabexate mesylate 77.9 114.9 92.0 83.1 75.0 69.8 81.1 70.9 77.3 89.6 94.2 89.1 117.6
    Rasagiline mesylate 76.9 141.9 92.0 88.1 75.8 71.8 87.7 74.2 91.3 88.3 103.4 94.0 104.9
    S-(+)-Rolipram 77.0 86.2 90.4 69.0 69.0 73.1 69.9 81.1 71.4 80.4 89.3 94.1 107.3
    Tebipenem pivoxil (L- 60.4 92.2 73.8 67.4 63.7 76.4 77.4 82.3 73.5 77.3 90.1 93.1 101.6
    084)
    Aliskiren hemifumarate 91.2 97.2 94.2 107.8 81.8 79.8 85.1 73.3 92.0 99.1 89.0 99.5 98.5
    Milrinone (Primacor) 101.4 104.1 98.5 99.0 130.3 86.2 92.9 101.1 90.9 98.5 92.0 90.5 111.8
    Novobiocin sodium 93.4 115.9 92.0 96.1 128.1 93.5 84.4 85.3 95.2 109.2 89.0 87.1 123.4
    (Albamycin)
    Ozagrel 74.7 102.5 91.2 77.7 98.5 80.6 93.9 69.4 77.7 101.8 101.4 80.6 118.3
    Pancuronium (Pavulon) 75.4 101.8 92.7 83.3 119.7 91.7 95.3 68.3 100.0 110.3 107.5 79.8 108.8
    Propafenone 95.8 109.2 86.0 108.8 79.8 92.5 84.7 61.1 94.1 119.7 104.4 105.3 113.2
    (Rytmonorm)
    Xylazine HCl 63.5 100.6 83.5 65.1 86.3 67.2 88.7 61.5 71.7 104.4 105.3 96.6 116.4
    L-Adrenaline 101.9 85.0 81.6 88.7 61.1 76.6 69.4 64.7 90.8 123.0 106.0 93.6 101.8
    (Epinephrine)
    Lonidamine 65.8 81.2 114.2 61.6 69.9 65.9 93.3 86.4 109.4 86.9 102.3 96.1 115.1
    Bisacodyl 88.0 122.0 100.4 89.2 107.2 93.6 132.3 104.3 66.7 65.0 83.7 85.5 96.0
    Sodium Nitroprusside 78.9 125.6 85.2 107.4 96.4 109.4 115.9 106.8 110.4 97.2 76.1 70.9 81.7
    Mefenamic acid 78.7 85.9 100.7 76.1 71.1 73.9 114.8 118.4 116.5 95.3 102.8 83.3 113.4
    Ticagrelor 60.1 73.6 94.5 125.5 100.5 76.0 114.5 86.0 85.0 83.1 84.1 79.6 93.7
    sulfacetamide sodium 64.9 76.7 98.7 75.9 81.4 79.8 117.8 120.3 70.0 110.2 70.8 81.8 111.5
    Levobetaxolol HCl 76.9 70.3 99.2 88.7 62.5 69.9 118.6 98.2 75.9 85.0 77.3 80.0 107.4
    Dexlansoprazole 75.1 82.8 119.8 104.7 89.8 69.6 85.8 84.9 74.5 72.1 104.5 102.0 72.2
    Chromocarb 63.4 72.8 95.6 67.6 81.8 78.8 100.3 97.2 61.1 100.4 88.3 72.5 110.1
    Guanethidine Sulfate 81.1 83.7 85.5 75.9 86.3 88.4 116.7 75.2 101.4 96.5 100.8 79.8 106.7
    Isoetharine Mesylate 97.0 96.1 76.5 81.6 96.6 91.7 91.0 88.3 76.7 102.7 71.6 100.2
  • Repeated experiments for growth inhibitory effects on cancer cell lines by various cardiovascular drugs in the present invention
  • According to the above mentioned cardiovascular drugs for cancer growth inhibition in Table 3, the inventors took the repeat experiments for the cardiovascular drugs to check the growth inhibitory effects of cancer cells by the cardiovascular drugs. The results were showed as Table. 4.
  • TABLE 4
    The inhibitory effect of cardiovascular drugs on various cancer cell lines
    AGS MKN-45 A549 H1650 TSGH-8301 T24
    Amlodipine besylate 12.18342 86.43411 110.3104 110.2477 36.2492 93.07934
    (Norvase)
    Nebivolol(Bystolic) 26.60363 52.82679 48.95406 87.37268 38.02989 97.6357
    Pimobendan 60.81009 65.23876 58.25261 77.77842 59.42484 74.23873
    (Vetmedin)
    Cilnidipine 76.93947 105.3923 67.8263 68.97714 95.88997 107.7523
    Losartan potassium 74.09621 82.7996 96.04947 77.1775 91.97894 66.27541
    Prazosin HCl 86.83206 70.11645 72.20906 100.6142 99.83677 88.51161
    Perindopril 87.13689 73.83094 71.92761 78.569 105.3434 87.89513
    Erbumine (Aceon)
    Nisoldipine (Sular) 64.72004 98.01894 48.91949 70.00318 77.9189 67.81543
    Amlodipine 16.51631 88.19584 89.21803 72.01455 36.20415 96.56012
    (Norvase)
    Benidipine 87.82976 92.86011 70.30445 64.52406 81.48268 60.98854
    hydrochloride
    Azelnidipine 90.22252 139.0039 87.46658 39.65028 115.122 79.46668
    Ouabain 16.61027 53.00617 15.12608 38.72274 43.58029 17.57783
    Disopyramide 95.87973 110.9738 99.43989 90.5041 115.4261 87.62175
    Phosphate
    Pitavastatin calcium 19.17312 61.30374 89.44373 49.9822 48.91635 52.63171
    (Livalo)
    Simvastatin (Zocor) 80.96248 92.58344 109.6818 79.82892 105.9187 89.62686
    Fluvastatin sodium 51.95546 65.29484 98.76315 73.07759 78.17048 71.79614
    (Lescol)
    Atorvastatin calcium 31.48172 84.18125 90.1462 69.54683 70.58927 78.47023
    (Lipitor)
    HepG2 Hep3B HCT116 LoVo HeLa C-33A
    Amlodipine besylate 95.00681 123.4192 78.25503 85.56338 101.287 33.71715
    (Norvase)
    Nebivolol(Bystolic) 42.12209 44.81568 81.90311 85.28787 52.00985 76.97273
    Pimobendan 87.23618 94.82416 53.63161 66.73545 34.00865 62.77014
    (Vetmedin)
    Cilnidipine 77.12693 92.70906 88.59966 53.71666 64.33688 92.99393
    Losartan potassium 93.9165 102.6817 105.8013 106.1105 83.41553 108.1531
    Prazosin HCl 87.24 115.7343 96.42385 95.70664 90.90437 97.23898
    Perindopril 99.43144 99.52974 64.99606 83.48715 66.66128 90.91624
    Erbumine (Aceon)
    Nisoldipine (Sular) 95.50526 130.2372 77.38842 76.88917 76.89186 65.96391
    Amlodipine 71.75803 99.21563 91.96059 90.33212 86.95599 38.17616
    (Norvase)
    Benidipine 83.57118 98.76207 90.62094 69.00425 92.92617 105.186
    hydrochloride
    Azelnidipine 100.8108 98.58296 111.283 59.86935 87.03299 123.2929
    Ouabain 38.05699 33.35996 15.8664 39.68181 23.12941 35.48352
    Disopyramide 108.9905 113.0039 93.97825 104.5373 102.7953 98.46569
    Phosphate
    Pitavastatin calcium 98.05696 96.33898 35.06809 65.14687 36.90614 74.75168
    (Livalo)
    Simvastatin (Zocor) 124.3915 113.5223 83.19968 89.30886 100.3977 112.4884
    Fluvastatin sodium 104.3733 108.8002 54.97113 99.98781 54.32329 89.50117
    (Lescol)
    Atorvastatin calcium 95.92241 91.85783 82.55431 103.0307 78.64343 96.94654
    (Lipitor)
    MDA- NIH-
    PC-3 MCF-7 MB231 OVCAR-3 TOV-21G AsPC-1
    Amlodipine besylate 73.55958 80.48625 82.71348 91.55643 93.54755 87.83891
    (Norvase)
    Nebivolol(Bystolic) 36.95159 27.04214 66.43548 86.76822 86.16763 88.66097
    Pimobendan 69.47215 53.94911 75.04087 74.72196 70.73536 69.30304
    (Vetmedin)
    Cilnidipine 61.39718 64.63051 86.26857 75.85887 62.8999 57.59939
    Losartan potassium 119.8879 87.64286 101.4346 98.7328 78.5729 86.43686
    Prazosin HCl 100.7353 87.60617 85.08244 88.88644 91.8658 80.37522
    Perindopril 81.06817 75.64154 63.78244 79.59739 71.22602 64.22167
    Erbumine (Aceon)
    Nisoldipine (Sular) 98.90966 86.64786 74.06174 68.14248 44.35767 78.75132
    Amlodipine 85.88287 63.42196 87.55328 90.31382 61.32005 89.03664
    (Norvase)
    Benidipine 88.48559 77.28047 77.34072 85.24836 47.45143 63.35622
    hydrochloride
    Azelnidipine 120.9111 60.82186 86.91866 102.4284 27.15468 53.57238
    Ouabain 25.76337 29.14322 44.49393 42.33431 15.89529 20.08356
    Disopyramide 103.4303 107.038 98.77022 102.8007 94.30529 77.1867
    Phosphate
    Pitavastatin calcium 27.53778 83.56777 39.0358 61.40586 21.78861 51.36252
    (Livalo)
    Simvastatin (Zocor) 92.77994 88.80292 71.08201 98.38307 63.61464 78.20757
    Fluvastatin sodium 32.11203 82.4571 43.03235 84.73175 50.48937 83.55133
    (Lescol)
    Atorvastatin calcium 56.4832 79.08152 47.83606 98.29788 34.04009 81.09956
    (Lipitor)
    BxPC-3 SAS U2OS A375 BCC 786-O
    Amlodipine besylate 99.10538 94.7983 71.05736 136.6675 102.9778 73.16328
    (Norvase)
    Nebivolol(Bystolic) 74.42236 75.56914 66.6423 44.93539 55.82216 38.30332
    Pimobendan 51.86991 51.11398 56.58073 44.3967 49.56082 39.63967
    (Vetmedin)
    Cilnidipine 68.6671 38.91442 43.14859 47.06953 60.17311 86.69656
    Losartan potassium 77.73778 95.71052 105.4483 96.64672 90.16032 96.33382
    Prazosin HCl 54.00243 114.3263 97.95575 77.91429 73.45319 79.5367
    Perindopril 49.97129 52.47616 73.98258 83.20685 58.70789 86.19895
    Erbumine (Aceon)
    Nisoldipine (Sular) 75.55234 48.80258 69.11154 51.46547 58.78716 49.50878
    Amlodipine 86.01719 99.20403 78.90455 81.57538 74.9299 81.41545
    (Norvase)
    Benidipine 73.78347 64.48332 54.15218 76.01467 74.60455 78.8709
    hydrochloride
    Azelnidipine 64.6017 76.82412 69.39511 101.1726 100.2223 86.81704
    Ouabain 27.01516 20.23483 22.80353 18.38812 25.61877 14.51443
    Disopyramide 69.94309 96.93263 98.72214 113.872 109.7018 102.4512
    Phosphate
    Pitavastatin calcium 59.77881 38.0374 43.44485 22.09494 26.77364 16.46038
    (Livalo)
    Simvastatin (Zocor) 81.82199 83.91121 65.60642 78.63685 57.35253 87.7969
    Fluvastatin sodium 79.10141 81.50136 91.20342 21.78962 27.03446 23.64486
    (Lescol)
    Atorvastatin calcium 81.02839 76.29143 86.25076 23.01045 41.49497 32.53672
    (Lipitor)

Claims (13)

1. A method for treating a cancer comprising: administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a cardiovascular drug or a pharmaceutical acceptable salt thereof.
2. The method of claim 1, wherein the cardiovascular drug is selected from the group consisting of peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, and intravenous (hemorrhoids) therapeutic agent.
3. The method of claim 2, wherein the peripheral vasodilator reaming enhancer is selected from the group consisting of Cilnidipine, Minoxidil, Prazosin HCl, Sildenafil citrate, Tadalafil (Cialis), Nicorandil (Ikorel), Lacidipine (Lacipil, Motens), Benidipine hydrochloride, Cilazapril monohydrate (Inhibace), Fosinopril sodium (Monopril), Almotriptan malate (Axert), Milrinone (Primacor), Avanafil, Lomerizine HCl, Histamine Phosphate, Chromocarb, and Pinacidil.
4. The method of claim 2, wherein the angiotensin converting agent inhibitor is selected from the group consisting of Benazepril hydrochloride, Losartan potassium, Perindopril Erbumine (Aceon), Irbesartan (Avapro), Candesartan (Atacand), Olmesartan medoxomil (Benicar), Enalaprilat dehydrate, Telmisartan (Micardis), Ramipril (Altace), Valsartan (Diovan), Enalapril maleate (Vasotec), Candesartan cilexetil (Atacand), Conivaptan HCl (Vaprisol), Azilsartan Medoxomil (TAK-491), and Eprosartan Mesylate.
5. The method of claim 2, wherein the hypotension and shock therapeutic agent is selected from the group consisting of L-Adrenaline (Epinephrine), DL-Adrenaline, and Methoxamine HCl.
6. The method of claim 2, wherein the diuretic is selected from the group consisting of Bumetanide, Furosemide (Lasix), Metolazone(Zaroxolyn), Silodosin (Rapaflo), Chlorothiazide, Trichlormethiazide (Achletin), Torsemide (Demadex), Hydrochlorothiazide, Indapamide (Lozol), Dichlorphenamide (Diclofenamide), Amiloride hydrochloride dehydrate, Solifenacin succinate, Methyclothiazide, Benzthiazide, Meticrane, Bendroflumethiazide, and Potassium Canrenoate.
7. The method of claim 2, wherein the antiarrhythmic agent is selected from the group consisting of Adenosine (Adenocard), Dofetilide (Tikosyn), Amiodarone HCl, Ibutilide fumarate, Propafenone (Rytmonorm), and Disopyramide Phosphate.
8. The method of claim 2, wherein the antiarralciton drug is selected from the group consisting of Dexrazoxane Hydrochloride, Ranolazine dihydrochloride, Nisoldipine (Sular), Ranolazine (Ranexa), Acadesine, Nifedipine (Adalat), Amlodipine besylate (Norvasc), Diltiazem HCl (Tiazac), Ticagrelor, and Oxprenolol HCl.
9. The method of claim 2, wherein the antihypertensive agent is selected from the group consisting of Bisoprolol, Doxazosin mesylate, Alfuzosin hydrochloride (Uroxatral), Nebivolol (Bystolic), Reserpine, Methyldopa (Aldomet), Eplerenon, Nimodipine (Nimotop), Betaxolol hydrochloride (Betoptic), Carvedilol, Metoprolol tartrate, Felodipine (Plendil), Amlodipine (Norvasc), Phentolamine mesilate, Imidapril (Tanatril) HCl, Aliskiren hemifumarate, Sodium Nitroprusside, Propranolol HCl, Levobetaxolol HCl, Esmolol HCl, (R)-(+)-Atenolol, Guanethidine Sulfate, and Lofexidine HCl.
10. The method of claim 2, wherein the anticoagulant thrombolytic agent is selected from the group consisting of Prasugrel (Effient), Cilostazol, Nafamostat mesylate, Clopidogrel (Plavix), Apixaban, Aminocaproic acid (Amicar), Dipyridamole (Persantine), Phenindione (Rectadione), Ticlopidine HCl, Ozagrel HCl, Argatroban, Bexarotene, Gabexate mesylate, and Ozagrel and Anisindione.
11. The method of claim 2, wherein the cardiac tonic is selected from the group consisting of Pimobendan (Vetmedin), Ampiroxicam, Digoxigenin, and Pindolol.
12. The method of claim 2, wherein the intravenous (hemorrhoids) therapeutic agent is selected from the group consisting of Edaravone (MCI-186), Daidzein, Ginkgolide A, and Bisacodyl.
13. The method of claim 1, wherein the cancer is selected from the group consisting of lung cancer, intestinal cancer, colorectal cancer, prostate cancer, liver cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
US15/521,536 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition Abandoned US20170304388A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/521,536 US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
PCT/CN2015/092768 WO2016062281A1 (en) 2014-10-24 2015-10-23 Applications of cardiovascular disease medicaments in preparing cancer-inhibiting pharmaceutical composition
US15/521,536 US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20170304388A1 true US20170304388A1 (en) 2017-10-26

Family

ID=55760314

Family Applications (7)

Application Number Title Priority Date Filing Date
US15/521,536 Abandoned US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,504 Abandoned US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/521,500 Abandoned US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Family Applications After (6)

Application Number Title Priority Date Filing Date
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,504 Abandoned US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/521,500 Abandoned US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Country Status (9)

Country Link
US (7) US20170304388A1 (en)
EP (3) EP3235497A4 (en)
JP (1) JP6539345B2 (en)
KR (1) KR102490334B1 (en)
CN (3) CN107106550A (en)
AU (2) AU2015335391B2 (en)
ES (1) ES2954860T3 (en)
TW (21) TWI621434B (en)
WO (21) WO2016062266A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3219705T3 (en) 2005-12-28 2020-08-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2016062266A1 (en) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Use of amlodipine in preparation of pharmaceutical composition inhibiting cancer
CN112675178A (en) 2014-12-22 2021-04-20 速达制药有限公司 Prevention and treatment of metastatic disease in cancer patients with thrombocythemia
WO2017116049A1 (en) * 2015-12-31 2017-07-06 경북대학교 산학협력단 Pharmaceutical composition for treating cancer and suppressing metastasis, containing sulfonamide-based compound as active ingredient
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (en) * 2016-06-15 2016-11-09 中南大学湘雅医院 Benserazide and pharmaceutically application in terms of preparing antineoplastic for the acceptable salt
WO2018072135A1 (en) * 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 Use of dihydropyridine calcium antagonist in treating cancer
CN108066345A (en) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 A kind of compound with antitumor action
RU2762896C2 (en) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing asenapine
RU2764443C2 (en) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene
WO2018227129A1 (en) * 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. Treatment of cancer with dihydropyridines
JP2019064976A (en) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 Anticancer agents
KR101933805B1 (en) 2017-10-17 2018-12-28 성균관대학교산학협력단 Pharmaceutical Composition for Preventing or Treating brain tumor comprising Oxeladin citrate as Active Ingredients
CN108186652A (en) * 2017-12-28 2018-06-22 深圳大学 Gap connects iuntercellular communication inhibitor 18-BETA-Glycyrrhetinic acid and is preparing the application in preventing and treating hepatocellular carcinoma drug
CA3089712A1 (en) 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗***股份公司 Transdermal therapeutic system comprising asenapine
FR3090084B1 (en) 2018-12-18 2023-10-13 Securengy Projectile for firearms or compressed air for liquid or powder delivery.
US20220072089A1 (en) * 2018-12-19 2022-03-10 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
US20220193020A1 (en) * 2019-04-04 2022-06-23 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
WO2020210643A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (en) * 2019-05-31 2019-08-30 天津科技大学 A kind of application of thioxanthene bromine class compound
CN110742890A (en) * 2019-10-24 2020-02-04 暨南大学 Application of lomerizine in preparation of anti-colon cancer drug
CN110840887A (en) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 Application of triclabendazole in preparation of medicine for treating breast cancer
CN110876800B (en) * 2019-11-18 2023-06-27 中南大学 Application of micafungin in preparation of antitumor drugs and antitumor drugs
CN111067899B (en) * 2020-01-08 2021-03-05 温州医科大学 Application of antimalarial primaquine phosphate in preparation of drugs for treating leukemia
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (en) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 Application of nitazoxanide and pharmaceutically acceptable salt thereof in preparation of medicines for treating bladder cancer
CN111557941A (en) * 2020-06-15 2020-08-21 浙江大学 Application of small-molecule inhibitor minoxidil of PLOD2 in tumor treatment
CN111848717A (en) * 2020-08-07 2020-10-30 四川大学 Compound for targeted regulation of mitochondrial energy metabolism and application and medicament thereof
WO2022033465A1 (en) * 2020-08-10 2022-02-17 萧乃文 Niclosamide and disulfiram pharmaceutical composition having synergistic anti-cancer effect and use thereof
CN112274525B (en) * 2020-12-04 2022-04-08 遵义医科大学 Chemotherapy pharmaceutical composition and application thereof
CN112336725A (en) * 2020-12-11 2021-02-09 吴照球 Novel medical application of trimethoprim
CN112569342A (en) * 2020-12-21 2021-03-30 中南大学 Application of caspofungin and/or pharmaceutical salt thereof in preparation of antitumor drugs and antitumor drugs
CN112569215A (en) * 2020-12-30 2021-03-30 东莞市人民医院 Application of domiphen bromide in preparation of medicine for preventing and treating colorectal cancer
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (en) * 2021-06-28 2022-12-30 四川大学 Use of FBXL2 activator for preparing medicine for treating EGFR driven lung cancer
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
CN117642164A (en) * 2021-09-09 2024-03-01 中国福利会国际和平妇幼保健院 Application of penfluridol in preparing medicine for treating endometrial cancer
CN115887455B (en) * 2022-08-04 2024-04-05 北京大学人民医院 Application of azelnidipine serving as calcium channel blocker in preparation of medicines for treating endometrial cancer
CN116570579A (en) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 Pharmaceutical composition containing agomelatine and fluvoxamine and application thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115412B1 (en) * 1993-10-01 2000-02-28 Syntex Inc Pharmaceutical composition and process for producing the same
CN1167418C (en) * 1994-12-28 2004-09-22 詹森药业有限公司 Use of nebivolol as anti-atherogenic
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
EP3461808A1 (en) * 2000-07-07 2019-04-03 Trustees of Tufts College 9-substituted minocycline compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR20070012618A (en) * 2003-09-18 2007-01-26 콤비네이토릭스, 인코포레이티드 Combinations of drugs for the treatment of neoplasms
ZA200603718B (en) * 2003-11-06 2007-09-26 Celgene Corp Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
EP1753425A4 (en) * 2004-05-12 2009-08-05 Biorunx Co Ltd A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
AU2005244988C1 (en) * 2004-05-21 2012-06-28 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
CN1279980C (en) * 2004-10-14 2006-10-18 孔庆忠 Anti solid tumor medicine composition
JP2006298781A (en) * 2005-04-15 2006-11-02 Geno Membrane:Kk Estrone-3-sulfate transporter activity inhibitor
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (en) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 Process for preparing valsartan
US20080199425A1 (en) * 2005-07-28 2008-08-21 Color Stitching(Stitching Color) Sensitization of Immune System Against Haptenized Melanoma Antigens
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2007112280A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (en) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 Micronization femara and its composition
CN101103976A (en) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 Oral medicinal composition containing anastrozole and preparation technology thereof
WO2008085875A2 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma)
CN101730526A (en) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (en) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (en) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 Application of amlodipine to preparation of medicaments for curing phoproliferative diseases
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (en) * 2009-07-22 2009-12-30 陈志龙 1 application of receptor antagonist in antitumor of angiotensin
CN101690816A (en) * 2009-08-16 2010-04-07 王丽燕 Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
CN101991553B (en) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 Exemestane tablet and preparation method thereof
CN101863806B (en) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 Preparation method of medicine (R)-Bicalutamide for resisting prostatic cancer
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
US9018438B2 (en) * 2010-07-29 2015-04-28 Kyoto University Screening method for anticancer drugs
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
CN102631354B (en) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 Pharmaceutical composition containing vitamin D and metformin
CN102688493B (en) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof
CN102813643B (en) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 Application of bumetanide in inhibition of hepatoma cell transfer
EP2760473A1 (en) * 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
US20140315809A1 (en) * 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
ES2384069B1 (en) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet and neuroblastic tumors
CN102600077B (en) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 Gemcitabine or gemcitabine salt nano-emulsion injecta and preparation method thereof
CN103536607A (en) * 2012-07-10 2014-01-29 邵金辉 Anti-tumor effects of oxytetracycline, propafenone and dipyrone
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20150224169A1 (en) * 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
BR112015006176B1 (en) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT
WO2014053650A1 (en) * 2012-10-04 2014-04-10 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
CN102872066B (en) * 2012-10-19 2014-07-02 厦门大学 Ivermectin and application of derivative thereof
AU2014204733B2 (en) * 2013-01-14 2016-09-08 Clinics Operations Limited Cancer drug and uses
CN103933569B (en) * 2013-01-22 2017-01-11 复旦大学 Anti-lung cancer pharmaceutical composition, its application, pill case and package
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (en) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 The anticancer usage of anagrelide and its derivative
CN103396419A (en) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 Tumour photodynamic therapy medicine dihydroporphin e6-15-ethyl ester and preparation method thereof
CN103536925B (en) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 Application of cardiac glycoside compound in treatment of non-small cell lung cancer
CN103622975B (en) * 2013-11-07 2016-06-15 广东药学院 Glipizide application in preparation tumor
SG11201607795UA (en) * 2014-04-08 2016-10-28 Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics
WO2016062266A1 (en) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Use of amlodipine in preparation of pharmaceutical composition inhibiting cancer

Also Published As

Publication number Publication date
WO2016062285A1 (en) 2016-04-28
EP3222278A1 (en) 2017-09-27
AU2015335391B2 (en) 2018-06-21
WO2016062289A1 (en) 2016-04-28
US10098852B2 (en) 2018-10-16
US20170216247A1 (en) 2017-08-03
TW201615218A (en) 2016-05-01
TW201615219A (en) 2016-05-01
TW201615221A (en) 2016-05-01
TW201615225A (en) 2016-05-01
WO2016062277A1 (en) 2016-04-28
TW201615189A (en) 2016-05-01
TWI663984B (en) 2019-07-01
WO2016062265A1 (en) 2016-04-28
WO2016062271A1 (en) 2016-04-28
TW201615223A (en) 2016-05-01
WO2016062272A1 (en) 2016-04-28
CN107106523A (en) 2017-08-29
WO2016062281A1 (en) 2016-04-28
EP3210604A4 (en) 2018-06-27
TW201615226A (en) 2016-05-01
WO2016062267A1 (en) 2016-04-28
KR20170084034A (en) 2017-07-19
TW201615186A (en) 2016-05-01
WO2016062290A1 (en) 2016-04-28
WO2016062287A1 (en) 2016-04-28
TW201615193A (en) 2016-05-01
WO2016062278A1 (en) 2016-04-28
US20170312260A1 (en) 2017-11-02
EP3222278C0 (en) 2023-06-14
EP3210604C0 (en) 2024-02-14
WO2016062270A1 (en) 2016-04-28
TWI652060B (en) 2019-03-01
AU2015335375A1 (en) 2017-05-18
TW201615222A (en) 2016-05-01
AU2015335375B2 (en) 2020-09-10
WO2016062286A1 (en) 2016-04-28
WO2016062275A1 (en) 2016-04-28
WO2016062283A1 (en) 2016-04-28
TW201615197A (en) 2016-05-01
US20170304387A1 (en) 2017-10-26
WO2016062266A1 (en) 2016-04-28
TWI621434B (en) 2018-04-21
US10045962B2 (en) 2018-08-14
TW201615191A (en) 2016-05-01
ES2954860T3 (en) 2023-11-27
JP6539345B2 (en) 2019-07-03
WO2016062274A1 (en) 2016-04-28
TW201615195A (en) 2016-05-01
TW201615220A (en) 2016-05-01
TWI672150B (en) 2019-09-21
TW201615194A (en) 2016-05-01
KR102490334B1 (en) 2023-01-18
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
AU2015335391A1 (en) 2017-06-01
EP3222278B1 (en) 2023-06-14
EP3222278A4 (en) 2018-06-20
CN107106550A (en) 2017-08-29
EP3210604A1 (en) 2017-08-30
TW201615196A (en) 2016-05-01
US20170304286A1 (en) 2017-10-26
EP3210604B1 (en) 2024-02-14
WO2016062291A1 (en) 2016-04-28
TW201615217A (en) 2016-05-01
CN106999470A (en) 2017-08-01
TWI663969B (en) 2019-07-01
TW201615192A (en) 2016-05-01
US20170304218A1 (en) 2017-10-26
WO2016062269A1 (en) 2016-04-28
TW201615224A (en) 2016-05-01
TW201615188A (en) 2016-05-01
TW201615184A (en) 2016-05-01
WO2016062279A1 (en) 2016-04-28
EP3235497A4 (en) 2018-06-13
JP2017532351A (en) 2017-11-02
WO2016062288A1 (en) 2016-04-28
EP3235497A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
US20170304388A1 (en) New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition
EP1572194B1 (en) Anti-cancer composition comprising dmxaa
Wang et al. Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo
ES2954361T3 (en) Methods of using dipivefrin
Álvaro-Villegas et al. Argon plasma coagulation and hyperbaric oxygen therapy in chronic radiation proctopathy, effectiveness and impact on tissue toxicity
AU2011265047B2 (en) Furanyl compounds and the use thereof
RU2012108144A (en) ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES
RU2431450C1 (en) Method of combination treatment of stage iiia-iiib locally advanced non-small-cell lung cancer
CN110638802A (en) Application of ATCA in preparation of medicine for treating tumors
Chaeichi-Tehrani et al. The therapeutic potential of targeting autophagy in the treatment of cancer
US20170312347A1 (en) Methods For Treating Cancers Using Ace Inhibitors, ARB, or Celecoxib and Olmesartan
CN104434948B (en) The pharmaceutical composition of a kind of anti-pancreatic cancer and application thereof
WO2016086776A1 (en) Antifungal compound formulation containing chlorogenic acid and application thereof
CN101879165B (en) Novel antihypertensive medicament compound preparation
Kuang et al. The Role of Histone Deacetylases in NLRP3 Inflammasomesmediated Epilepsy
US20200405727A1 (en) New alk inhibitor senolytic drugs
KR102412690B1 (en) Treatment method for cancer patients with severe renal dysfunction
CN106310268A (en) Pharmaceutical composition for treating triple-negative breast cancer
US20220151995A1 (en) Pharmaceutical composition for treating cancer and suppressing metastasis, containing sulfonamide-based compound as active ingredient
TWI472324B (en) Use, pharmaceutical composition and kit for applying metformin and sodium butyrate in kras mutation cancer treatment
WO2013085902A1 (en) Combination therapy methods for treating an inflammatory breast cancer
Farhangnia et al. The Role of Inflammasome in Cancers and Potential Therapeutic Targets
Abd-Alhaseeb et al. Angiotensin (1-7) Antagonist Diminished the Anti-Tumor Effect of Olmesartan in Tumor Cell Lines Grown In-vitro and In-vivo
WU et al. COMBINED PHYTOCHEMICAL SULFORAPHANE AND DIETARY FIBER INULIN CONTRIBUTE TO THE PREVENTION OF ER-NEGATIVE BREAST CANCER VIA PI3K/AKT/MTOR PATHWAY AND MODULATING GUT MICROBIAL COMPOSITION
WO2003022268A1 (en) A combination and method of treatment of cancer utilizing a cox-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa) reductase inhibitor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION